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Background: Obesity is common in type 2 diabetes (T2DM) and is associated with increased risk of morbidity and
all-cause mortality. This analysis describes weight changes associated with insulin detemir initiation in real-life
clinical practice.
Methods: Study of Once-Daily Levemir (SOLVE) was a 24-week international observational study of once-daily
insulin detemir as add-on therapy in patients with T2DM receiving oral hypoglycaemic agents (OHAs).
Results: 17,374 participants were included in the analysis: mean age 62 ± 12 years; weight 80.8 ± 17.6 kg; body
mass index (BMI) 29.2 ± 5.3 kg/m2; diabetes duration 10 ± 7 years; HbA1c 8.9 ± 1.6%. HbA1c decreased by 1.3 ± 1.5%
during the study, with insulin doses of 0.27 ± 0.17 IU/kg. Patients with higher BMI had higher pre-insulin HbA1c,
and similar reductions in HbA1c with insulin therapy. Weight decreased from 80.8 ± 17.6 kg to 80.3 ± 17.0 kg
(change of −0.6 [95% CI −0.65; -0.47] kg), with 35% of patients losing >1 kg. Patients with the highest pre-insulin
BMI lost the greatest amount of weight: BMI < 25: +0.8 [95% CI: 0.6; 0.9] kg, 25 ≤ BMI < 30: -0.2 [95% CI: -0.3; -0.8] kg,
30 ≤ BMI < 35: -1.0 [95% CI: -1.1; -0.8] kg; BMI ≥ 35: -1.9 [95% CI: -2.2; -1.6] kg. Minor hypoglycaemia decreased with
increasing BMI: 2.3 and 1.3 events per patient year for BMI <25 and ≥ 35, respectively.
Conclusions: Overall, patients with poorly controlled T2DM achieved significant reductions in HbA1c after initiation
of once-daily insulin detemir therapy, without weight gain. The favourable impact of insulin detemir on weight may
not apply to other insulin preparations.
Trial registrations: ClinicalTrials.gov, NCT00825643 and NCT00740519
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The prevalence of type 2 diabetes mellitus (T2DM) and
obesity is increasing worldwide. An estimated 80-90% of
patients with T2DM are overweight, and obesity is ac-
knowledged as a major factor in the development of
T2DM [1]. Obesity in patients with T2DM is common
and is frequently a major component of the metabolic
syndrome, an insulin-resistant state that is characterized* Correspondence: jean-francois.yale@mcgill.ca
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reproduction in any medium, provided the orby a group of risk factors, which together confer an in-
creased risk for cardiovascular disease and diabetes [2].
Insulin resistance is characterised by a reduced sensitiv-
ity in body tissues to the action of insulin, resulting in
impaired glucose uptake in muscle and fat, and dimin-
ished insulin suppression of hepatic glucose output. As a
result of insulin resistance, patients with T2DM require
higher concentrations of insulin to stimulate peripheral
glucose uptake and to suppress hepatic glucose produc-
tion, than are needed in patients without diabetes [3].
It has become increasingly clear that physicians should
give equal attention to weight management as they do to. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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robust evidence to demonstrate that even a modest re-
duction in weight of between 5-10% in patients with
T2DM has a beneficial effect in terms of improved gly-
caemic control, lowered blood pressure and an improve-
ment in lipid profile [8,9]; and also lowers the risk of
progression of diabetes, as well as cardiovascular disease
[7]. Excessive weight is also an independent risk factor
for increased morbidity and mortality in patients with
T2DM [10].
Even though the early stages of T2DM may be managed
with lifestyle changes and oral hypoglycaemic agents
(OHAs), many patients with T2DM will eventually re-
quire insulin therapy. Typically, the initiation of insulin
therapy has been associated with weight gain. Fear of
weight gain by either patients and/or their health care
providers is known to be one key reason why initiation
of insulin is delayed despite being indicated on clinical
grounds [11,12].
The objectives of this pre-specified sub-analysis from
the Study of Once-Daily Levemir (SOLVE) study was to
observe the impact of insulin detemir on weight and
various cardio-metabolic parameters. To provide con-
text, glycaemic control and hypoglycaemia are also
briefly considered.
Methods
SOLVE was a 24-week observational study in which insu-
lin detemir was evaluated as add-on therapy in patients
with T2DM already receiving OHAs. The study was
conducted in ten countries (Canada, China, Germany,
Israel, Italy, Poland, Portugal, Spain, Turkey and the UK).
There were some variations between countries with re-
spect to patient eligibility which have been reported previ-
ously [13]. The study was conducted in accordance with
the Declaration of Helsinki. Ethical approval was obtained
from local institutional review boards or independent eth-
ics committees prior to the commencement of the study
in each of the participating countries. The IRBs approving
the study in the participating countries were: Health
Canada (Canada), State Food and Drug Administration
(China), Federal Institute for Drugs and Medicinal Devices
(Germany), Ministry of Health (Israel), Agenzia Italiana del
Farmaco (Italy), Ministry of Health (Poland), Comissão de
Ética para a Saúde do Hospital do Divino Espírito Santo
(Portugal), Spanish Agency for Medicines (Spain), Ministry
of Health (Turkey), Medicines and Healthcare Products
Regulatory Agency (UK).
Patients
For all countries, the decision to initiate basal insulin pre-
ceded inclusion into the study and was made solely on the
basis of a normal clinical evaluation as part of the patients’
routine diabetes management. Patients were recruited andfollowed up at primary and specialist health care facilities
between February 2008 and January 2011.
Data were collected at baseline (including data prior to
insulin initiation, where relevant), at 12 weeks (interim
visit) and at 24 weeks (final visit), and were derived from
patient recall, the patient’s clinical records and the pa-
tient’s self-monitored blood glucose (SMBG) diary.
The study excluded female patients who were pregnant,
breast-feeding, intending to become pregnant within the
next 6 months, or were not using adequate contraceptive
methods. Patients had to be aged over 18 years to partici-
pate in four countries and over 6 years to participate in six
countries. Withdrawal criteria included change in the
once-daily dosing regimen of insulin detemir during the
study, pregnancy, or the intention to become pregnant
during the study. In these situations, the decision to dis-
continue insulin detemir was at the physician’s discretion.
Patients could also withdraw from the study at any time
and continue to receive normal clinical care.
Endpoints
The primary outcome in SOLVE was the incidence of
serious adverse drug reactions (SADRs) including severe
hypoglycaemic events. Secondary efficacy endpoints in-
cluded: glycosylated haemoglobin A1c (HbA1c), fasting
blood glucose (FBG), self-monitored blood glucose
(SMBG), weight and lipid profile. Physical measurements
including blood pressure, weight, waist and hip circum-
ference were recorded at baseline, interim and final
visits. Information was also recorded about insulin ther-
apy including dose and dose adjustments, and concomi-
tant OHA therapy. Analysis of all major variables
including change in body weight was performed for the
total cohort and for various subgroups.
As the focus of this sub-analysis was the impact of in-
sulin detemir initiation on weight and other cardio-
metabolic parameters, the findings presented here fo-
cuses on four baseline body mass index (BMI) subgroups
(BMI <25 kg/m2, 25 ≤ BMI <30 kg/m2, 30 ≤ BMI <35 kg/
m2, BMI ≥35 kg/m2). These cut off points were pre-
specified on the basis of being widely used in clinical tri-
als of insulin and because of their use as internationally
recognised definitions of overweight (BMI ≥25), obesity
(BMI ≥30), and severe obesity (BMI ≥35) [14,15].
While detailed results are presented for these BMI
subgroups, a summary of the major primary and second-
ary endpoints are also given for the entire cohort.
Statistical methods
Two main analysis sets were used in this sub-analysis.
The Full Analysis Set (FAS) comprised all enrolled pa-
tients who had been prescribed basal insulin detemir at
baseline. The Effectiveness Analysis Set (EAS) com-
prised all patients from the FAS with a final visit
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HbA1c, weight measurement or record of
hypoglycaemia at both baseline and final visit. The EAS
was used for the analyses of HbA1c, blood glucose and
lipid profiles. The FAS was used for the reporting of
baseline characteristics, and analysis of all other vari-
ables (including ADRs and hypoglycaemia).
Continuous variables were summarized using mean and
standard deviation, and categorical data were summarized
as counts (percentages). Missing observations were not in-
cluded in the calculation of percentages.
Statistical testing of data before and after treatment with
insulin detemir was analysed using paired t-tests for con-
tinuous variables, the Wilcoxon test for ordinal categorical
variables, and the McNemar test for discrete variables
such as incidence of hypoglycaemic events.
The influence of predictor variables on the reduction
in weight ≥1 kg was evaluated by logistic regression
analysis. The basic model included age (in 5-year gro-
upings), gender, duration of diabetes (in quartiles), pre-
insulin HbA1c (as a continuous variable) and BMITable 1 Baseline characteristics
Total
cohort BMI <25
N (%) 17,374 3,534 (20.8%)
Age (years) 62 ± 12 62 ± 12
Male (%) 53% 55%
Weight (kg) 80.8 ± 17.6 62.8 ± 8.5
BMI (kg/m2) 29.2 ± 5.3 22.8 ± 1.7
Waist circumference (cm) 99.3 ± 15.1 85.3 ± 9.0
Hip circumference (cm) 104.0 ± 13.4 94.5 ± 8.0
Waist:hip ratio 0.94 ± 0.11 0.90 ± 0.09
Blood pressure (mmHg)
Systolic 136 ± 17 131 ± 16
Diastolic 81 ± 10 78 ± 9
FBG (mmol/L) 10.3 ± 3.1 9.8 ± 3.0
HbA1c (%) 8.9 ± 1.6 8.7 ± 1.8
Lipd profile (mmol/L)
Total cholesterol 5.1 ± 1.2 5.0 ± 1.1
HDL 1.2 ± 0.4 1.3 ± 0.4
LDL 2.9 ± 1.0 2.9 ± 0.9
Triglycerides 2.1 ± 1.2 1.8 ± 1.2
Duration of Diabetes (years) 10 ± 7 10 ± 8
Duration of OHA treatment 8 ± 7 9 ± 8
Number of OHAs
1 OHA 29.9% 33.7%
2 OHAs 54.1% 50.4%
>2 OHAs 16.0% 15.8%
Continuous measures are shown as mean ± standard deviation.subgroup. The effects of previous medical history and
number of OHAs were assessed for the basic model
parameters. Additional assessment of the effects of indi-
vidual OHAs during treatment with insulin, change in
OHA prescribing at the time of insulin initiation and
insulin dose (mean and final insulin dose) were adjusted
for basic model parameters and number of OHAs pre-
scribed pre-insulin. All parameters were included in the
final backward elimination model, with the criteria for
selection set at p < 0.05. All testing used two-sided tests
at α = 0.05 level of significance.
Results
A total of 17,374 participants were included in the FAS.
A total of 2,761 patients withdrew from the study, of
which 1,548 (n = 1548/17372, 8.9%) patients did so at or
before the interim visit and 1,213 (n = 1213/17372,
7.0%) discontinued at or before the final visit. Reasons
for study withdrawal included lost to follow-up (34%;
n = 934), discontinuation of OHA (5%; n = 144), discon-
tinuation of study drug (11%; n = 297), incorrect studyBody mass index (BMI) at baseline
25≤ BMI < 30 30 ≤ BMI < 35 BMI ≥ 35
6,811 (40.1%) 4,218 (24.9%) 2,405 (14.2%)
62 ± 12 62 ± 11 60 ± 11
58% 52% 39%
76.4 ± 9.2 88.6 ± 11.0 104.5 ± 15.6
27.4 ± 1.4 32.1 ± 1.4 38.8 ± 3.3
96.0 ± 9.7 107.3 ± 9.4 119.5 ± 12.4
102.3 ± 8.4 110.7 ± 9.7 123.3 ± 14.0
0.93 ± 0.08 0.97 ± 0.10 0.98 ± 0.13
135 ± 16 139 ± 16 140 ± 18
81 ± 9 82 ± 10 82 ± 11
10.0 ± 2.9 10.4 ± 3.1 10.8 ± 3.1
8.8 ± 1.5 9.0 ± 1.5 9.1 ± 1.5
5.1 ± 1.2 5.1 ± 1.2 5.0 ± 1.2
1.2 ± 0.3 1.2 ± 0.4 1.2 ± 0.3
3.0 ± 1.0 2.9 ± 1.0 2.8 ± 1.0
2.1 ± 1.2 2.2 ± 1.2 2.4 ± 1.2
10 ± 7 10 ± 7 9 ± 7
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sulin (15%; n = 417), ADR (3%; n = 87), and other rea-
sons (21%; n = 588). The reason for study withdrawal
was missing for 13% of patients (n = 363). Patients could
report more than one reason for study withdrawal.Patient demography
Baseline characteristics for the total cohort as well as for
BMI subgroups are summarised in Table 1. The mean
weight (±SD) at baseline was 80.8 ± 17.6 kg for the over-
all cohort and the mean BMI was 29.2 ± 5.3 kg/m2. Pa-
tients with a BMI ≥35 kg/m2 at baseline tended to beTable 2 Glycaemic control, hypoglycaemia, weight, size, lipid
BMI <25 25 ≤ BM
(n = 3534) (n =
Glycaemic control
HbA1c (%)
Final visit 7.4 ± 1.2 7.5
Change −1.4 ± 1.7** −1.3 ±
FBG (mmol/L)
Final visit 6.8 ± 1.7 7.0
Change −3.0 ± 3.0** −3.0 ±
Hypoglycaemia Incidence (events per patient year)
Severe hypoglycaemia
Pre-insulin 0.057 0.0




Final visit 2.390 2.0
Change +0.635** +0.
Weight (kg)
Change +0.75 [0.60; 0.90] −0.16 [−0
Change in Anthropometric measurements (cm)
Waist circumference 0.10 [−0.12; 0.32] −0.51 [−0
Hip circumference −0.32 [−0.56;- 0.07] −0.67 [−0
Change in lipid profile (mmol/L)
Total cholesterol −0.26 [−0.31; -0.20] −0.31 [−0
HDH cholesterol +0.01 [−0.01; 0.03] +0.01 [0
LDL cholesterol −0.15 [−0.19; -0.10] −0.16 [−0
Triglycerides −0.23 [−0.29; -0.17] −0.26 [−0
Change in blood pressure (mmHg)
Systolic −3.03 [−3.59; -2.46] −3.77 [−4
Diastolic −1.26 [−1.62; -0.91] −2.31 [−2
Continuous measures are shown as mean ± standard deviation or mean [95% confi
**p < 0.001.
*p < 0.01.younger, and there were a higher proportion of female
patients relative to the other BMI subgroups.
Glycaemic control (as measured by HbA1c and FBG)
deteriorated in association with increasing baseline
BMI. HbA1c was 9.1 ± 1.5% in patients with a BMI ≥35
kg/m2 compared with 8.7 ± 1.8% in patients with a BMI
<25 kg/m2.
Baseline blood pressure and triglycerides also in-
creased in association with increasing BMI. Mean sys-
tolic blood pressure at baseline was 131 ± 16 mmHg in
patients with a BMI <25 kg/m2 and 140 ± 18 mmHg in
patients with a BMI ≥35 kg/m2. Mean triglycerides levels
at baseline were 2.4 ± 1.2 mmol/L in patients with a BMIprofile and blood pressure by BMI subgroup
I < 30 30 ≤ BMI < 35 BMI ≥ 35
6811) (n = 4218) (n = 2405)
± 1.1 7.7 ± 1.1 7.9 ± 1.3
1.5** −1.3 ± 1.5** −1.3 ±1.5**
± 1.6 7.2 ± 1.8 7.7 ± 2.2







.26; -0.07] −0.99 [−1.13; -0.84] −1.89 [−2.16; -1.63]
.72; -0.29] −1.23 [−1.57; -0.88] −2.18 [−2.64; -1.73]
.88; -0.47] −0.86 [−1.35; -0.36] −1.30 [−1.90; -0.70]
.35; -0.26] −0.34 [−0.40; -0.27] −0.35 [−0.42; -0.27]
.00; 0.02] +0.01 [−0.01; 0.03] +0.02 [−0.01; 0.04]
.20; -0.12] −0.18 [−0.24; -0.12] −0.20 [−0.28; -0.13]
.31; -0.22] −0.34 [−0.40; -0.28] −0.44 [−0.52; -0.37]
.23; -3.31] −5.06 [−5.70; -4.43] −5.10 [−5.97; -4.24]
.59; -2.03] −2.22 [−2.60; -1.84] −2.24 [−2.77; -1.71]
dence interval].
Figure 1 Insulin dose in units and units per kilogram at final visit by BMI subgroup.
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with a BMI <25 kg/m2.
Glycaemic efficacy
Glycaemic control improved in each of the BMI sub-
groups, with statistically significant reductions in HbA1c
and FBG at the final visit compared with pre-insulin
values in all subgroups (Table 2).
The insulin dose according to BMI subgroups are shown
in Figure 1. The figure demonstrates the contrast between
the trend to increasing unit dose but similar unit per kilo-
gram dose with with increasing BMI.Hypoglycaemia
There were statistically significant reductions in the rates
of severe hypoglycaemia in all BMI subgroups (Table 2).
Whilst there was an increase in the incidence of minor
hypoglycaemia in three of the four BMI subgroups, there
was a reduction in the rate of minor hypoglycaemia in
the subgroup of patients with the largest BMI (−0.41
events per person year), although this did not reach stat-
istical significance (p = 0.116).Weight
Small reductions in weight, BMI, and waist and hip cir-
cumference were observed across the total cohort fol-
lowing the initiation of insulin detemir. Mean weight
changed by −0.56 kg, [95% CI −0.65; -0.47] from a pre-
insulin value of 80.8 ± 17.6 kg to a final visit value of
80.3 ± 17.0 kg (p < 0.001). Similarly, mean BMI changed
by −0.2 kg/m2 from a pre-insulin value of 29.2 ± 5.3 kg/
m2 to a final visit value of 29.0 ± 5.2 kg/m2 (p < 0.001).
Mean waist circumference changed by −0.69 cm (from
98.3 ± 14.8 cm to 97.6 ± 14.4 cm; p < 0.001) and meanhip circumference changed by −0.66 cm (from 103.5 ±
12.9 cm to 102.8 ± 12.6 cm; p < 0.001).
The degree of weight change was proportional to the
pre-insulin BMI (Table 2): patients with the highest pre-
insulin BMI ≥35 kg/m2 lost the greatest amount of weight
(−1.9 kg; p < 0.001), while patients with pre-insulin BMI
<25 kg/m2 had a weight gain (+0.75 kg; p < 0.001).
The proportion of patients who lost more than 1kg
during the study increased in association with larger
pre-insulin BMI: (49% of patients with BMI ≥35 kg/m2
compared with 42%, 32% and 19% of patients with
pre-insulin BMI of: 30 ≤ BMI <35 kg/m2, 25 ≤ BMI <30
kg/m2, and <25 kg/m2, respectively).
Blood pressure and lipids
Treatment with insulin detemir was associated with im-
provements in patients’ lipid profiles. At the final visit, there
were significant reductions (p < 0.001) in total cholesterol
(−0.30 mmol/L), low-density lipoprotein (LDL) cholesterol
(−0.16 mmol/L) and triglycerides (−0.29 mmol/L) across
the entire cohort. Significant improvements in lipid profile
also occurred in all BMI subgroups, with a tendency to-
wards greater improvements in subgroups with a higher
BMI (Table 2), particularly for triglycerides.
There was a significant decrease in systolic and diastolic
blood pressure across the entire cohort at the final visit
compared with pre-insulin values (systolic: mean change −4
mmHg, p < 0.001; diastolic: mean change −2 mmHg,
p < 0.001). While blood pressure tended to increase with
baseline BMI, reductions in blood pressure during the study
were also greater in patients with larger BMI (Table 2).
OHA use
Some differences in OHA therapy prior to insulin initi-
ation were apparent between BMI subgroups (Table 3).
Table 3 Proportion of patients using oral antidiabetic drugs (OHA) prior to insulin initiation and at end of study
Body mass index (BMI) at baseline
BMI <25 25 ≤ BMI < 30 30 ≤ BMI < 35 BMI ≥ 35
Biguanide
Baseline 71.2% 81.8% 85.8% 87.0%
Final Visit 65.1% 80.5% 85.2% 86.5%
Change −6.1% −1.3% −0.6% −0.5%
Glinides
Baseline 19.5% 16.3% 14.7% 13.5%
Final Visit 24.7% 18.8% 17.1% 16.1%
Change +5.2% +2.5% +2.4% +2.6%
Alpha Glucosidase Inhibitor
Baseline 19.9% 12.2% 8.6% 7.8%
Final Visit 21.4% 12.5% 7.8% 6.6%
Change +1.5% +0.3% −0.8% −1.2%
Sulphonylureas
Baseline 57.9% 58.5% 61.7% 60.3%
Final Visit 41.4% 43.3% 46.4% 45.3%
Change −16.5% −15.2% −15.3% −15.0%
Thiazolidinediones
Baseline 10.9% 11.3% 12.8% 15.2%
Final Visit 7.3% 7.9% 7.7% 8.2%
Change −3.6% −3.4% −5.1% −7.0%
Dipeptidyl peptidase IV Inhibitors
Baseline 3.8% 5.9% 7.9% 9.6%
Final Visit 2.8% 5.2% 6.5% 7.2%
Change −1.0% −0.7% −1.4% −2.4%
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insulin use of biguanides, thiazolidinediones and dipep-
tidyl peptidase IV (DPP-IV) inhibitors in patients with
larger BMI; whereas there was a trend in the opposite
direction concerning the pre-insulin use of glinides and
α-glucosidase inhibitors. With the exception of glinide
and α-glucosidase inhibitor use, the proportion of pa-
tients using each of the classes of OHA decreased from
pre-insulin to the end of the study, with the greatest per-
centage reductions occurring in patients with BMI ≥35
kg/m2 (Table 3). The largest change in the use of OHA
during the study was with respect to sulphonylurea, which
decreased by 15.0% in the subgroup with BMI ≥35 kg/m2
and by 16.5% in the subgroup with BMI <25 kg/m2. The
proportion of patients using glinides during the study,
however, increased in all BMI subgroups.
Predictors of weight gain
Logistic regression analysis was performed in order to
evaluate demographic and treatment parameters associ-
ated with weight loss of 1 kg or more. Results of thebasic model, and basic model adjusted effects are shown
in Table 4. In the basic model, lower pre-insulin HbA1c
and increased pre-insulin BMI were associated with a sig-
nificantly increased odds ratio (OR) of weight loss ≥ 1 kg.
Adjusting for basic model parameters, the OR of weight
loss ≥ 1 kg decreased with increasing number of pre-
insulin OHAs. After additionally adjusting for the num-
ber of pre-insulin OHAs, higher doses of insulin and
the concomitant use of thiazolidinediones were also as-
sociated with significantly lower odds of weight loss ≥ 1
kg; whereas a reduction in the number of concomitant
OHAs prescribed or the use of biguanides at the time
of insulin initiation was associated with an increase in
the odds of weight loss ≥ 1 kg.
In the final backward elimination model, pre-insulin
HbA1c, gender, BMI, the number of OHAs, and the
concomitant use of metformin (positive), α-glucosidase
inhibitor (positive), thiazolidinedione (negative) and
DPP-IV inhibitor (negative) all had significant independ-
ent effects on the odds of weight loss ≥ 1 kg; with the
largest effect determined by pre-insulin BMI (Figure 2).
Table 4 Results of logistic regression models of demographic and study treatment parameters associated with weight
loss ≥ 1 kg by final visit
Parameter Category Odds
ratio
95% confidence interval p value
Lower Upper
Basic Model
Baseline HbA1c (%) 0.927 0.905 0.950 <0.0001
Age (years) ≥75 0.902 0.776 1.049 0.6660
≥70 to < 75 0.969 0.834 1.126
≥65 to < 70 0.959 0.829 1.109
≥60 to < 65 1.015 0.885 1.165
≥55 to < 60 1.020 0.889 1.171
≥50 to < 55 0.945 0.813 1.098
< 50 (reference group) 0 . .
Gender Female vs. Male 0.916 0.849 0.989 0.0229
Duration of Diabetes (years) >13 0.945 0.844 1.059 0.1681
>8.5 to ≤13 0.884 0.795 0.983
>5 to ≤8.5 0.898 0.807 1.000
≤5 (reference group) 0 . .
BMI (kg/m2) ≥35 3.351 2.934 3.827 <0.0001
≥30 to <35 2.389 2.130 2.681
≥25 to <30 1.709 1.538 1.899
<25 (reference group) 0 . .
Adjusted for Basic Model Parameters
Previous History
Pre-insulin Hypoglycaemia Yes vs. No 1.113 0.940 1.318 0.4518
Microvascular disease Yes vs. No 1.050 0.967 1.141 0.4390
Macrovascular disease Yes vs. No 1.021 0.934 1.116 0.4052
Number of OHAs Prior to Insulin Initiation >2 OHAs 0.853 0.756 0.963 0.0003
2 OHAs 0.928 0.850 1.012
1 OHA (reference group) 0 . .
Adjusted for Basic Model Parameters and Number of OHAs Prior to Insulin Initiation
Change in OHA Regimen Increased 0.965 0.784 1.189 0.0002
Decreased 1.150 1.035 1.278
Unchanged (reference group) 0 .
Concomitant OHA Treatment
Metformin Yes vs. No 1.167 1.066 1.279 0.0009
Sulphonylureas Yes vs. No 0.962 0.888 1.043 0.3485
Glinides Yes vs. No 0.939 0.848 1.041 0.2315
α-Glucosidase Inhibitors Yes vs. No 1.102 0.973 1.248 0.1262
Thiazolidinediones Yes vs. No 0.789 0.675 0.921 0.0027
DPP-IV Inhibitors Yes vs. No 0.845 0.710 1.005 0.0576
Final Insulin Dose (U/kg) >0.3 0.871 0.773 0.981 0.0241
0.2 to <0.3 0.887 0.791 0.994
0.1 to <0.2 0.973 0.877 1.079
< 0.1 (reference group) 0 . .
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Table 4 Results of logistic regression models of demographic and study treatment parameters associated with weight
loss ≥ 1 kg by final visit (Continued)
Mean Insulin Dose (U/kg) >0.27 0.836 0.740 0.945 0.0193
0.20- < 0.27 0.880 0.776 0.997
0.13- < 0.20 0.944 0.850 1.049
<0.13 (reference group) 0
The effect size is expressed as Odds Ratios (OR) with 95% confidence intervals (CI).
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final insulin dose as measured in U/kg) was not inde-
pendently associated with weight loss ≥ 1 kg.
Discussion
This large observational study of patients with T2DM
demonstrated that the initiation of once daily insulin
detemir in patients already receiving OHA therapy was
effective in improving glycaemic control, and was associ-
ated with a low incidence of hypoglycaemia and an over-
all mean reduction in weight across the entire cohort.
Mean weight reductions occurred in all patient sub-
groups with a BMI ≥25 kg/m2. This weight-sparing ef-
fect was most apparent in overweight and obese
patients, with changes in weight of up to −1.9 kg in the
subgroup of patients with BMI ≥35 kg/m2. Treatment
with insulin detemir was also associated with improve-
ments in other cardio-metabolic parameters including
lipid profile and a reduction in blood pressure.
Although baseline HbA1c was higher in patients with
larger BMI, the reduction in HbA1c was comparable
across all BMI subgroups (−1.3 to −1.4%). Conventional
understanding would suggest that increased insulin re-
sistance in patients with higher BMI necessitates higherFigure 2 Demographic and treatment parameters associated with we
elimination logistic regression model. Error bars indicate 95% confidencinsulin per kilogram dosing. In the present study, the
unit dose of insulin increased with increasing BMI, how-
ever, the unit per kilogram dose was similar across all
four BMI subgroups (0.26-0.29 units/kg at the final
visit). The fact that the majority of patients did not reach
the usual HbA1c target of 7.0% in the absence of any in-
crease in hypoglycemic episodes suggests a degree of
clinical inertia in adjusting insulin dosages. This is sup-
ported by the lower insulin dosages in the present study
compared to those reported in treat-to-target trials (0.4
and 0.6 U/kg) [16-19]. It is possible that the effects on
body weight would have been different with a more ag-
gressive insulin initiation regimen, or over longer pe-
riods of follow-up.
Recent reviews examining the effect of OHA treatment
either alone or in combination with insulin have shown
that, in general, the sulphonylureas and thiazolidinediones
promote weight gain, DPP-IV inhibitors are weight neu-
tral, while biguanides (Metformin) promote weight loss
[5,20,21]. In the present analysis, the logistic regression
model showed that both biguanides (increased odds) and
thiazolidinediones (decreased odds) were independent
predictors of weight loss ≥1 kg at final visit. However, a
greater proportion of patients with larger BMI wereight loss ≥ 1 kg by final visit – results of a final backward
e intervals.
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more, the use of thiazolidinediones decreased across all
BMI subgroups (to a greater extent in patients with larger
BMI). In this study, the type, frequency and dosing of
OHAs could be modified at the discretion of the phys-
ician. The pattern of OHA treatment observed in this
study may also have been related to country-specific usage
of these medications. It is possible that differences in
OHA therapy observed prior to and during the study, may
have contributed to weight change differences between
the BMI groups; however, it is unlikely, given the effect
size of BMI subgroup on the odds of weight loss ≥1 kg
(Table 4), that BMI related effects on weight loss during
treatment with insulin detemir can be explained by the
differences in OHA therapy alone.
Basal insulin analogues such as insulin detemir were
developed using recombinant techniques to provide a
more physiological profile than human intermediate
insulin preparations, and have been shown to be effect-
ive and safe in several randomized controlled trials, with
a reduced risk of hypoglycaemia compared with trad-
itional human insulins [22]. Additionally, insulin detemir
is associated with a unique overall weight-sparing effect
in patients with diabetes. The results from SOLVE
add to a growing body of data, including randomised
controlled trials pooled analyses, and other real-world
data demonstrating a weight-sparing effect of insulin
detemir [23-26]. The weight-sparing effect appears to be
greatest in the most overweight patients [24,26]. This re-
lationship is of considerable clinical significance since it
is the heaviest group of patients that would also be
expected to be at the greatest risk of developing
macrovascular (and in particular, cardiovascular) compli-
cations. By contrast, other long acting insulin analogues,
such as insulin glargine, do not appear to share this
weight–sparing effect – an analysis of 4555 patients with
BMI < and ≥ 30 demonstrated a mean weight increase in
both groups (+1.2 kg and +1.1 kg, respectively) [27].
The mechanisms for the weight-sparing effect of insu-
lin detemir, independent of changes in concomitant
OHA therapy, remain to be elucidated, but various pos-
sibilities have been suggested [28,29]. One explanation is
that the reduced risk of hypoglycaemia with insulin
detemir compared with traditional human insulin prod-
ucts may reduce the need for defensive snacking (over
eating in order to try to prevent hypoglycaemic epi-
sodes). However, insulin glargine, which reduces hypo-
glycaemia to a similar degree, does not appear to have
this weight-sparing effect. A second explanation relates
to its novel method of prolonging action via acylation
and albumin binding, resulting in preferential hepatic
utilisation, thus suppressing hepatic glucose output with-
out promoting lipogenesis in the periphery. A third
hypothesis is that insulin detemir may be more effectivethan traditional human insulin in signalling satiety
within the central nervous system [30]. Further research
of the mechanisms underlying insulin detemir’s weight-
sparing properties is required.
Given the observational nature of this study, definitive
conclusions about the extent to which insulin detemir
was responsible for all the measured changes are limited.
Only patients initiating basal insulin therapy with insulin
detemir were included in the analyses. This may mean,
for example, that the cohort is not representative of pa-
tients requiring additional prandial glucose coverage at
the time of insulin initiation. Nevertheless, SOLVE is the
largest study of insulin initiation in real-life clinical prac-
tice, and otherwise broad inclusion criteria and the focus
on insulin initiation in type 2 diabetes are important
study strengths.Conclusions
The SOLVE study adds to the growing body of evidence
showing that insulin detemir is associated with an overall
weight-sparing effect which has not been demonstrated by
other insulin preparations. This weight-sparing property
appears to be most pronounced in the heaviest patients, a
group that stands to gain the most benefit from losing
weight. The management of weight is essential at all stages
of treatment of patients with T2DM and should be given
equal importance to achieving glycaemic control owing to
the association with risk of developing cardiovascular
complications.
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